Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$664.31B | 63.2x | 0.68 | US$738.21 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$369.31B | 26.5x | -0.49 | US$153.24 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.1% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$330.43B | 78.8x | -7.06 | US$186.91 | -7.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$282.28B | 19.1x | 0.97 | US$62.54 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$257.68B | 26.9x | -1.03 | US$37.65 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$257.68B | 26.9x | -1.03 | US$302 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$216.75B | 31.1x | 1.8 | US$136.64 | -9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$216.75B | 31.1x | 1.8 | US$68.46 | -7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$205.90B | 12.2x | 0 | US$81.50 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.1% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$203.60B | 18.2x | -1.02 | US$104.67 | -7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$203.60B | 18.2x | -1.02 | US$105.85 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2% Downside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$158.29B | 39x | -1.02 | US$294.26 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$133.68B | 286.4x | -3.17 | US$107.28 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.1% Downside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$130.50B | 16.3x | 0.06 | US$22.99 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$129.35B | 22x | 7.83 | US$51.97 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$111.96B | -12.6x | 0.06 | US$55.31 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.2% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$85.37B | 31.4x | -23.53 | US$683.11 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.5% Downside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$74.62B | 1.58 | US$22.46 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$74.43B | 22.6x | -0.49 | US$18.38 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$74.43B | 22.6x | -0.49 | US$36.53 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$73.53B | 28.2x | 2.5 | US$74.44 | -7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$67.86B | 27.9x | 3.72 | US$151.73 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$56.18B | 18.4x | -12.9 | US$25.33 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.6% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$46.73B | 25x | 0.63 | US$9.89 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.1% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$46.62B | 33.9x | 2.15 | US$30.07 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$46.62B | 33.9x | 2.13 | US$14.73 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$46.24B | 28.3x | 0.85 | US$24 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | US$31.39B | 26.8x | 0.14 | US$81.73 | -7.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.7% Upside | Upgrade to Pro+ | |
Cardinal Health | NYSE | Healthcare | Pharmaceuticals | US$31.32B | 24.1x | 0.27 | US$129.63 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.4% Upside | Upgrade to Pro+ | |
Alnylam | NASDAQ | Healthcare | Pharmaceuticals | US$30.76B | -110.5x | -3.27 | US$235.57 | -10.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | US$27.84B | 12.1x | 0.07 | US$25.01 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.8% Upside | Upgrade to Pro+ | |
Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | US$21.71B | -7.8x | -0.66 | US$5.50 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.7% Upside | Upgrade to Pro+ | |
Biogen | NASDAQ | Healthcare | Pharmaceuticals | US$18.04B | 11.1x | 0.31 | US$122.98 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.3% Upside | Upgrade to Pro+ | |
Sandoz | OTC Markets | Healthcare | Pharmaceuticals | US$17.88B | US$41.36 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.8% Upside | Upgrade to Pro+ | |||
Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$17.88B | 16.2x | -0.64 | US$31.11 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.1% Upside | Upgrade to Pro+ | |
Teva ADR | NYSE | Healthcare | Pharmaceuticals | US$17.02B | -11.5x | 0.06 | US$13.80 | -7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | US$16.96B | -43.6x | 0.03 | US$9.19 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
Intracellular Th | NASDAQ | Healthcare | Pharmaceuticals | US$14.02B | -183.1x | -3.73 | US$131.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.1% Upside | Upgrade to Pro+ | |
Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | US$13.49B | 11.8x | 0.93 | US$7.66 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.1% Upside | Upgrade to Pro+ | |
Incyte | NASDAQ | Healthcare | Pharmaceuticals | US$11.70B | 384.2x | -3.81 | US$60.58 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
Biomarin Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$11.53B | 27x | 0.21 | US$60.25 | -10.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
Dr. Reddy’s Labs ADR | NYSE | Healthcare | Pharmaceuticals | US$10.81B | 17.2x | 6.64 | US$12.36 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | US$9.37B | 24.2x | -0.54 | US$28.35 | -7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viatris | NASDAQ | Healthcare | Pharmaceuticals | US$9.07B | -14.5x | 0.01 | US$7.62 | -6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sino Biopharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.95B | 36.2x | 0.63 | US$9.75 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shanghai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.58B | 15.4x | 0.66 | US$7.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | US$8.18B | 13.9x | -0.7 | US$0.56 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.11B | 22.4x | 0.44 | US$31.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corcept | NASDAQ | Healthcare | Pharmaceuticals | US$7.84B | 54.7x | 1.34 | US$74.45 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eisai Co | OTC Markets | Healthcare | Pharmaceuticals | US$7.57B | 19.3x | 0.17 | US$6.48 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |